Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$5.38B
sum of reported positions
Reported positions
125
Changes vs prior quarter
121
39 new · 24 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 124 measured positions in 8 quarters, the typical new or larger position finished +0.6 pts against the S&P 500 and 52% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 15.5M | $631M | 11.7% | |
| 6.78M | $344M | 6.4% | |
| 258K | $309M | 5.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $4.88B | $5.38B |
| Positions | 110 | 125 |
| Biggest line | — | Edgewise Therapeutics 12% |
| 3.43M |
| $189M |
| 3.5% |
| 2.72M | $184M | 3.4% |
| 916K | $171M | 3.2% |
| 2.21M | $119M | 2.2% |
| 2.56M | $112M | 2.1% |
| 7.17M | $107M | 2.0% |
| 3.03M | $105M | 2.0% |
| 584K | $87.6M | 1.6% |
| 93K | $86.2M | 1.6% |
| 663K | $85.2M | 1.6% |
| 1.81M | $83.3M | 1.5% |
| 230K | $77M | 1.4% |
| 835K | $75.5M | 1.4% |
| 13.7M | $73.2M | 1.4% |
| 547K | $72.8M | 1.4% |
| 3.24M | $71.9M | 1.3% |
| 262K | $71.1M | 1.3% |
| 973K | $69.1M | 1.3% |
| 161K | $67M | 1.2% |
| 8.29M | $66.4M | 1.2% |
| 244K | $65.2M | 1.2% |
| 164K | $65.2M | 1.2% |
Enliven Therapeutics (ELVN)
7.96M → 6.78M shares (−15%)
Eli Lilly (LLY)
237K → 258K shares (+9%)
Mbx Biosciences (MBX)
3.64M → 3.43M shares (−6%)
Astrazeneca (AZN)
670K → 916K shares (+37%)
Structure Therapeutics (GPCR)
1.48M → 2.21M shares (+50%)
Sionna Therapeutics (SION)
3.53M → 2.56M shares (−28%)
Guardant Health (GH)
435K → 584K shares (+34%)
Argenx (ARGX)
137K → 93K shares (−32%)
Uniqure N.V. (QURE)
2.14M → 1.81M shares (−15%)
Praxis Precision Medicines (PRAX)
173K → 230K shares (+33%)
Edwards Lifesciences (EW)
1.23M → 835K shares (−32%)
Prelude Therapeutics (PRLD)
10.9M → 13.7M shares (+26%)
Abivax (ABVX)
466K → 547K shares (+17%)
Dyne Therapeutics (DYN)
2.92M → 3.24M shares (+11%)
Cg Oncology (CGON)
948K → 973K shares (+3%)
UnitedHealth (UNH)
161K shares
Ascendis Pharma A (ASND)
244K shares
Humana (HUM)
164K shares
Cogent Biosciences (COGT)
322K → 1.68M shares (+422%)
Boston Scientific (BSX)
2.38M → 1.48M shares (−38%)
Intuitive Surgical (ISRG)
209K → 158K shares (−24%)
Mineralys Therapeutics (MLYS)
2.05M → 2.11M shares (+3%)
Odyssey Therapeutics (ODTX)
3M shares
Xenon Pharmaceuticals (XENE)
1.06M → 892K shares (−16%)
Arcutis Biotherapeutics (ARQT)
2.04M shares
